12526 High Bluff Drive, Suite 260
About Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.
Founder & CEO: Dr. John Hood
Co-Founder & Interim CMO: Dr. Catriona Jamieson
Co-Founder & CFO: Raghu Saripalli
President and CBO: Charles McDermott
Sr. VP, Commercial: Randy Adams
Sr. VP, Technical Operations: Jeff Barker
13 articles about Impact Biomedicines
The U.S. Food and Drug Administration approved Impact’s Inrebic for the treatment for adult patients with certain types of myelofibrosis, cancers of the bone marrow.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
The company said it will acquire Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis.
Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase II and III Myelofibrosis Clinical Trials
The results of these trials have been published in leading peer-reviewed journals.
Impact Biomedicines announced that it has achieved the first milestone in the Company’s previously disclosed $90 million financing with Oberland Capital, triggering the closing on the first tranche of $20 million.